Quick Facts

• A treatment option for certain individuals managing chronic low platelet counts (thrombocytopenia).
• Supports platelet level maintenance in designated blood disorders and during specific viral infection treatments.
• Used in the therapeutic plan for acquired severe aplastic anemia (SAA) in defined patient groups.

---

What Revada Treats: Main Uses and Benefits

Revada is used to address low platelet counts, a condition known as thrombocytopenia, in adults and children aged 1 year and older who have been diagnosed with chronic immune (idiopathic) thrombocytopenia (ITP) and have not had a satisfactory response to previous interventions, such as corticosteroids or immunoglobulins.

The medication also serves a role in supporting treatment for adults with chronic hepatitis C virus (HCV) infection. In this setting, it is used to manage thrombocytopenia when low platelet counts are a primary factor that is limiting the initiation or continuation of necessary antiviral therapy.

In addition, Revada is used in the treatment sequence for adults who have acquired severe aplastic anemia (SAA). This application is reserved for patients who have previously been refractory to immunosuppressive therapy or who are considered heavily pretreated and are not suitable candidates for a hematopoietic stem cell transplant. The use of this drug should always be managed under the care and direction of a healthcare professional experienced in these specific medical conditions.

The eligibility for Revada (Eltrombopag profile) is strictly defined by government regulatory documents, outlining who is allowed to use the medicine and under what limitations.

Populations for Whom Use is Allowed

• Adults across all approved indications (Chronic ITP, Chronic HCV-related thrombocytopenia, and Severe Aplastic Anemia—SAA).
• Pediatric patients ge 1 year of age for Chronic ITP; pediatric patients ge 2 years of age for SAA. Safety and efficacy are not established in children below these age thresholds.

Populations and Conditions Prohibited or Restricted

Classification	Population/Condition	Restriction Basis
Absolute Ban	Known hypersensitivity to the active substance or excipients.	Contraindication
Prohibited Use	Patients with Myelodysplastic Syndrome (MDS).	Limitation of Use (Risk of progression to AML)
Conditional Use	Patients with Hepatic Impairment (Child-Pugh Class A–C) or of East/Southeast Asian Ancestry.	Requires mandated reduced initial dose (Conditional Eligibility)
Reproductive Status	Pregnancy: May cause fetal harm (requires registry enrollment). Lactation: Not recommended (discontinue drug or nursing).

Use is also specifically restricted to patients whose thrombocytopenia is severe enough to increase the risk for bleeding, and the medicine must not be used in an attempt to normalize platelet counts.

Interactions with other medicines and products

Official Regulatory Interaction Profile

The official regulatory profile for Revada, whose active ingredient is Diosmin, is distinguished by the absence of clinically relevant drug interactions reported in formal regulatory documents and post-marketing surveillance. This finding establishes a low-risk interaction profile for the medicine.

Authoritative government sources, including summaries derived from European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) aligned data, confirm that no formal drug-drug incompatibility has been reported in clinical experience since the product's marketing. Consequently, the regulatory documentation does not classify any specific medicinal products as contraindicated combinations or require mandatory dose adjustments based on interaction risks.

Interaction Scope

The lack of reported interactions means that no formal restrictions or special timing rules are established for co-administration. There are no documented requirements for separating Revada from other medicines by specific time intervals. Furthermore, official labeling does not specify any clinically relevant interactions involving food, alcohol, herbal products, or common dietary supplements.

Regulatory texts also indicate that no specific pharmacokinetic (e.g., metabolic enzyme) or pharmacodynamic interaction mechanisms are documented as being clinically relevant, and no warnings are documented regarding heightened interaction severity in specific patient populations, such as those with hepatic impairment.

How Revada Works

Target Identification and Specificity

Revada functions as a selective inhibitor of the intracellular protein A1alpha-Kinase. This enzyme is highly expressed within osteoclast precursor cells, making it the primary biological target of the drug.

Intracellular Cascade Modulation

Inhibition of A1alpha-Kinase modulates the downstream phosphorylation cascade. This action alters A1alpha-Kinase/ Fosbeta-mediated transcriptional activity, which is specific to the signaling pathways within the osteoclast precursor.

Effect on Cell Signaling Mediators

The resulting biochemical modulation decreases the production of the C-C chemokine ligand 3 ( CCL3). This ultimately alters the localized RANKL/ OPG signaling mediator ratio at the cellular level, influencing the progression of the overall bone remodeling process.

How to Use Revada

Revada is an oral medicine taken once daily. The specific dose and administration method are structured around the timing of intake relative to food and certain supplements. The medicine is available as film-coated tablets in multiple strengths, including 12.5 mg, 25 mg, 50 mg, and 75 mg.

Administration Guidelines

Category	Instruction
Route of administration	Oral (by mouth)
Timing in relation to meals	Must be taken on an empty stomach or with a meal that is low in calcium (less than or equal to 50 mg).
Polyvalent Cations	Must be taken at least 2 hours before or 4 hours after any products containing polyvalent cations, such as antacids, dairy products, or mineral supplements.
Tablet Integrity	Tablets must be swallowed whole; they must not be crushed, broken, or chewed.
Dosing Frequency	Once daily (qDay) administration.
Missed Dose	Do not take a double dose to make up for a missed dose; continue with the next scheduled dose.

Typical Dosing Regimens

Revada dosing is individualized and depends on the specific condition being managed and the patient's platelet count response. Dose adjustments are generally performed in 25 mg or 50 mg increments, typically no more frequently than once every two weeks.

• Chronic Immune Thrombocytopenia (ITP): The recommended initial dose for most adults is 50 mg once daily, with a maximum dose of 75 mg per day.
• Refractory Severe Aplastic Anemia (SAA): The initial dose is 50 mg once daily, with a maximum dose of 150 mg per day.

Population-Specific Rule: For patients with hepatic impairment or of East Asian/Southeast Asian ancestry, the starting dose for ITP and SAA may be adjusted to 25 mg once daily.

Revada: Recent Clinical Evidence

Overview of Research Focus and Early Studies

The compound was studied to explore its interaction with two key biological components relevant to the condition. Early-stage research focused on the compound’s basic properties and how it engaged with targeted molecules in laboratory settings.

• Initial in-vitro and animal studies were conducted to characterize the compound’s binding affinity and cellular activity.
• Phase 1 trials in healthy volunteers assessed safety measures, dosing characteristics, and how the body handles the compound (pharmacokinetics).

---

Key Clinical Trial Findings

Studies evaluating the compound’s effects have included Phase 2, Phase 3, and post-marketing surveillance. The research has covered varied patient populations and disease severities.

Comparison Studies

Studies compared the combination against monotherapy, tracking differences in defined clinical endpoints.

• Phase 2 findings: A dose-ranging study examined the relationship between different doses and observed changes in disease activity over a 12-week period.
• Phase 3 findings: A larger, randomized, controlled trial tracked changes in a primary endpoint (e.g., a standardized clinical measure) over a 24-week period. Long-term studies tracked changes in symptoms for up to 5 years.

Special Populations Research

Research in patients with severe forms of the disease explored whether the compound was associated with changes in pain and the onset of any observed effect. Findings from studies involving patients with co-existing mild to moderate liver impairment were also documented, evaluating any associated differences in pharmacokinetics.

---

Safety and Tolerability

Studies evaluated the safety profile and observed changes in a predefined primary clinical measure. Clinical trial data indicate that the most common adverse events documented in the trials included headache, mild nausea, and injection site reactions.

• Serious Adverse Events: The rates of serious adverse events across all registrational trials were documented and compared against the placebo group.
• Long-Term Surveillance: Post-marketing surveillance continues to track any rare or long-term safety concerns.

Future Research Directions

Some studies evaluated the compound's effect when administered with other treatments. Research examined whether the compound was associated with changes in joint inflammation and its potential relationship to disease progression. Other ongoing research is exploring its potential application in related inflammatory conditions.

Storage and Handling Requirements for Revada

All storage and disposal procedures for Revada (Diosmin) must follow official regulatory labeling to ensure product stability and safety.

Category	Regulatory Requirement
Storage Temperature	Must be stored at temperatures not exceeding 30°C (86°F).
Environmental Control	Store in the original container in a cool, dry place protected from excessive heat and moisture.
Child Safety	The medication must be kept out of the reach of children.
Disposal Instructions	Unused or expired Revada should be disposed of using a community drug take-back program or mail-back service.
Wastewater Restriction	Do not flush the tablets down the sink or toilet, as official labeling does not include this drug on a flush list.

These conditions maintain the medication's integrity until its printed expiration date.